摘要
目的观察心力衰竭应用沙库巴曲缬沙坦比照厄贝沙坦的临床有效性。方法将2018年1月至2019年6月在我院就诊患者132例分为2组,对照组给予厄贝沙坦治疗,观察组给予沙库巴曲缬沙坦治疗。观察两组疗效,治疗前后LVEF、NT-proBNP、LVEDD、cTnT,治疗6个月后再住院、心源性死亡及高血钾发生率。结果在治疗效果的总改善率、治疗6个月后再住院率、LVEF、NT-proBNP方面,观察组更具优势(P<0.05)。结论心力衰竭应用沙库巴曲缬沙坦疗效更确切,可显著改善心功能,遏制心衰复发。
Objective To observe clinical effect of salkubatril valsartan compared with irbesartan in patients with heart failure.Methods We chose 132 patients in our hospital from January 2018 to June 2019,divided them into two groups,control group was treated with irbesartan,and observation group with sarkubatrovalsartan.Observed curative effect,LVEF,NT proBNP,LVEDd,cTnT before and after treatment,rehospitalization,cardiogenic death and hyperkalemia incidence after 6 months of treatment.Results Total improvement rate of treatment effect,rehospitalization rate after 6 months of treatment,LVEF and NT proBNP of observation group had more advantages than those of control group,(P<0.05).Conclusion Sakubatrovalsartan can achieve accurate effect on heart failure,improve cardiac function and prevent recurrence of heart failure significantly.
作者
王帅
WANG Shuai(Department Of Cardiology,Jihua Group General Hospital,Jilin,Jilin,132021)
出处
《智慧健康》
2020年第36期176-177,共2页
Smart Healthcare
